Lifestyle ⏱ Half-life: Not well characterized in published pharmacokinetic data. Discontinued

Adipotide

Adipotide (FTPP / Prohibitin-Targeting Peptide)

Updated March 15, 2026

Evidence at a Glance

Regulatory statusDiscontinued
Prohibitin/ANXA2-targeting proapoptotic peptidomimetic; Phase 1 dosed 2012, development halted for nephrotoxicity.
Human evidenceLimited
Animal evidenceModerate

Adipotide produced ~11% weight loss in obese rhesus monkeys, but its human Phase 1 program was discontinued due to kidney toxicity.

What the research does not support

  • It is not a proven or approved weight-loss therapy; human development was stopped over renal toxicity.
  • It does not selectively spare healthy tissue; its dose-limiting effect was damage to the kidneys.
  • Its dramatic fat loss in monkeys has never been shown to be safe or reproducible in people.
Half-Life
Not well characterized in published pharmacokinetic data.
Mol. Weight
~2800 g/mol

What is Adipotide?

Adipotide takes a radically different approach to fat reduction — rather than modifying metabolism or appetite, it directly targets and destroys the blood vessels that supply white adipose tissue, causing fat cell death through ischemia.

Research Applications

Targeted fat tissue ablation, obesity research, vascular targeting studies, and prohibitin biology.

Dosage Information (Research Use)

Primate research: 0.5-1 mg/kg subcutaneously. Human safety not established. Research use only.

Reconstitution & Handling

Standard BAC water reconstitution.

Half-Life & Pharmacokinetics

Not well characterized in published pharmacokinetic data.

Reported Observations in Literature

Renal toxicity reported in primate studies (kidney is highly vascularized). Dehydration effects noted. Not considered safe for human use.

Key Research References

  • Barnhart KF, et al. “A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys.” Sci Transl Med. 2011

How Adipotide Works

Adipotide is a chimeric peptide with two functional domains: a targeting sequence (CKGGRAKDC) that binds prohibitin on blood vessels supplying white fat tissue, and an apoptosis-inducing sequence D(KLAKLAK)2 that destroys those vessels. This cuts blood supply to fat deposits, causing adipose tissue death.

Research Findings

Dramatic fat loss observed in primate studies (rhesus monkeys lost ~11% body weight in 4 weeks). However, renal toxicity was observed, limiting clinical development.

Dosage & Administration

Primate research: 0.5-1 mg/kg subcutaneously. Human safety not established. Research use only.

Safety & Side Effects

Renal toxicity reported in primate studies (kidney is highly vascularized). Dehydration effects noted. Not considered safe for human use.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Sequence CKGGRAKDC-GG-D(KLAKLAK)2 (chimeric)
Molecular Weight ~2800 g/mol
Half-Life Not well characterized in published pharmacokinetic data.
Available Sizes 5mg
Storage Lyophilized: -20°C. Reconstituted: 2-8°C.

Key Research References

  • Barnhart KF, et al. "A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys." Sci Transl Med. 2011

Related Peptides

View all →
Melanotan I
Lifestyle
Linear melanocortin analog with selective MC1R activity for melanogenesis research without the broad receptor effects of Melanotan II.
View Profile →
PT-141
Lifestyle
Melanocortin receptor agonist researched for sexual function through central nervous system pathways rather than vascular mechanisms.
View Profile → Buy Now
SLU-PP-332
Lifestyle
SLU-PP-332 is a synthetic small molecule, not a peptide. It is an aryl acylhydrazone — 4-hydroxy-N’-[(E)-naphthalen-2-ylmethylidene]benzohydrazide, C18H14N2O2, molecular…
View Profile → Buy Now